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Leishmaniasis are a group of diseases, endemic in many
parts of the world.1,2) Leishmaniasis are mostly prevalent in
poor developing countries evident by the growing number of
cases seen in AIDS patients3) and the occurrence of vis-
cerotropic Leishmania tropica disease among Persian Gulf
War Participants.2,3) The disease is transmitted by the mem-
bers of the genus Leishmania which is a protozoal parasite.
These parasitic protozoans are digenetic and have two dis-
tinct stages in their life cycle. The motile flagellated pro-
mastigote stage lives in the alimentary tract of the sand fly
vector, while the non-motile amastigote stage resides inside
the macrophages of mammalian hosts.4)
Leishmanial infections include three major syndromes: cu-
taneous, visceral and mucosal leishmaniasis. The basic treat-
ment consists in the administration of sodium stibogluconate
(pentostam), meglumine (glucantime) or pentamidine. Com-
mon problem with this basic treatment especially in Kala-
azar, mucosal leishmaniasis is the developing drug resistance
of the parasite.5) In addition, the low efficacy of pentavalent
antimony in the treatment of patients coinfected with AIDS
is often noticed.6) These problems prompted the development
of new anti-leishmanial drugs.7—10)
Curcumin is a yellow-orange dye derived from the rhi-
zome of the plant Curcuma longa. It has long been used as a
naturally occurring medicine for the treatment of inflamma-
tory diseases. Curcumin (difleruloyl methane) is a natural
phenolic compound. It is a potent anti-tumor agent having
anti-inflammatory and anti-oxidant properties. It induces
apoptosis in cancer cells11,12) and inhibits TPA-induced Pro-
tein kinase C (PKC) activity.13) It has also shown anti-bacter-
ial, anti-fungal and anti-trypnosomal activity.1,14,15) A recent
study has also shown action against the promastigote forms
of Leishmania major.16)
In this report we evaluated the actions of curcumin against
the promastigote forms of different reference and local leish-
manial strains in vitro. We also evaluated the activity of cur-
cumin against the axenic amastigote like cells (AALC) of L.
major in vitro.
MATERIALS AND METHODS
Parasite Cultures All the promastigote cultures of both
the reference and local Pakistani leishmanial strains were
maintained in blood agar based bi-phasic Evan’s modified
Tobie’s medium supplemented with RPMI-1640 with 25 mM
TES at 25 °C. The reference leishmanial strains were ob-
tained from London School of Hygeine and Tropical Medi-
cine. The reference strains of promastigotes that were used
include L. major (JISH118), L. tropica (K27) and L. infan-
tum (LEM3437). Local leishmanial strains used in this study
include L. major (MHOM/PK/88/DESTO) in the promastig-
ote and AALC stage (see below). Other local strains used in
the promastigote stage include L. tropica and L. infantum.
The long term continuous culture of axenic amastigote like
cells (AALC) of L. major (MHOM/PK/88/DESTO) strain
was successfully established. Briefly, AALC cells were ob-
tained from the promastigotes by the gradual adaptation of
cells to increasing temperature and falling pH in RPMI
medium supplemented with 20% fetal calf serum (FCS).
This was performed in a stepwise fashion through the pas-
sage and adaptation of cells to new culture condition (higher
temperature and lower pH reaching a temperature of 32 °C
and a pH of 5.1, in a long process of stabilization to each
new growing condition).
Chemicals Unless otherwise stated, all the chemicals in-
cluding curcumin were obtained from Sigma/Aldrich.
Viability Test Assays on Promastigotes: Parasites in the
promastigote stage were transferred from Evan’s modified
Tobie’s medium to RPMI-1640 supplemented with 10% 
fetal bovine serum (FBS) buffered with 25 mM TES, pH 7.2.
They were grown in bulk at 25 °C. They were centrifuged at
2500 g for 10 min and early log phase promastigotes were
collected. The parasites were washed twice with RPMI
(without FBS) and resuspended in the complete medium to
achieve a final concentration of 106 parasties/ml. In order to
get the 100% growth inhibition concentratrion (TGI) and
LD50 of drugs, serial dilutions of curcumin and pentamidine
(taken as control) in the promastigote culture medium (100
m l) were performed in 96-well microtiter plate. Subsequently
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105 promastigotes in 100 m l of culture medium were added to
each well and the plate was incubated at 25 °C for 72 h. Neg-
ative controls (culture without curcumin) were on the same
plate. At the end of the incubation time the plate was shaken
mechanically over a plate shaker and parasites were counted
by the help of a hemocytometer. Dose dependent viability
curves were obtained subsequently.
For Amastigotes: The AALC drug susceptibility determi-
nations were performed by using the same method applied
for promastigotes. Serial dilutions of drugs (curcumin and
pentamidine) in culture medium of L. major (100 m l/well)
were performed in a 96 well microtiter plate; then 100 m l of
AALC in RPMI medium (pH 5.1) from the culture in the log.
phase of growth at a concentration of 53105 cells/ml was
added and incubated at 32 °C for 72 h. After 72 h, the plate
was shaken mechanically and parasites were counted. Dose-
dependent viability curve was obtained subsequently. All the
results for the promastigotes as well as for the AALC were
triplicated.
Statistical Analysis Two sample independent t test with
significant p values (,0.05) was used to compare the drug
susceptibilities of the parasites at both stages. Each experi-
ment was triplicated (n53).
RESULTS AND DISCUSSION
In this report, we evaluated the actions of curcumin against
the promastigote forms of reference leishmanial strains and
local leishmanial strains in vitro. As shown in Figs. 1, 2 and
Table 1, curcumin showed cytotoxicity against both the local
and reference leishmanial strains in the promastigote stage.
No major differences in the degree of susceptibility of para-
March 2002 387
Fig. 1. Effect of Curcumin on Reference Leishmanial Strains (Promastigotes)
Fig. 2. Effect of Curcumin on Local Leishmanial Strains (Promastigotes)
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Table 1. Effect of Pentamidine on Local and Effect of Curcumin on Local and Reference Leishmanial Strains
Effect of pentamidine Effect of curcumin on Effect of curcumin on
on local strains local strains reference strains
IC50 values (mM)
L. major 10.560.52 L. major 4.360.21 L. major 4.560.22
L. tropica 9.860.49 L. tropica 5.960.29 L. tropica 5.760.28
L. infantum 11.160.55 L. infantum 5.960.29 L. donovani 5.960.29
Each experiment was repeated at least three times (n53) with consistent results indicating that the assays used in this study were highly reproducible. A 65% standard error
was calculated for all the results, which is always associated with hemocytometer counting. Curcumin proves to be more potent than pentamidine (t512.7, p,0.001) whereas no
significant difference was found b/w the susceptibility of the curcumin on the local and reference leishmanial strains. (t50, p..5).
Fig. 3. Effect of Pentamidine on Local Leishmanial Strains (Promastigotes)
Fig. 4. Effect of Curcumin on L. major (AALC)
sites occurred during the study. Whereas 100% killing of all
the strains was noticed at 13.5 mM. The leishmaniacidal ef-
fects of curcumin if compared with pentamidine clearly
shows that curcumin has a higher potency in vitro (t512.7,
p,0.001) (Fig. 3, Table 1).
The reference strains were observed to have a higher
growth rate and faster doubling time therefore they were ex-
pected to have higher IC50 values but the results showed that
there is no significant difference b/w the potency of curcumin
on both the reference and local leishmanial strains (t50,
p,0.5).
Each experiment was repeated at least three times with
consistent results indicating that the assays used in this study
were highly reproducible. A 65% standard error was calcu-
lated for all the results, which is always associated with he-
mocytometer counting.
There is no doubt that leishmania can be cultured most
easily in the promastigote stage. Thus it is easier to perform
such kind of assays on promastigotes but the main draw back
attributed to these assays is the heterogeneity of results com-
pared with those obtained with intracellular amastigotes or
with in vivo effect.17) In order to further strengthen the study,
both drugs were checked on AALC (Fig. 4, Table 2). In a
previous study no difference was found in the sensitivity of
AALC and intracellular amastigtoes to antimonial prepara-
tions assayed.18—20) Thus these AALC may prove to be reli-
able to check the sensitivities of different drugs against leish-
mania.
As shown in Fig. 4, curcumin proves to be far more potent
then pentamidine against AALC of L. major strain which
further strengthens the fact about its leishmaniacidal activity
(t514.2, p,0.001). However in order to further prove its an-
tileishmanial activity curcumin needs to be checked against
various other strains in AALC and intracellular amastigotes.
Previous studies have shown that curcumin easily pene-
trates into the cytoplasm of mammalian cells. It accumulates
in the membranous structures such as plasma membrane, en-
doplasmic reticulum and nuclear envelope.11) It has also been
shown to suppress mitrogen induced proliferation of blood
mononuclear cells and inhibit the proliferation of rabbit vas-
cular smooth muscle cells stimulated by fetal calf serum
(FCS). However the mechanism of action of curcumin
against leishmania still needs to be explored and awaits fur-
ther studies.
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Table 2. Effect of Curcumin and Pentamidine on AALC
Drug IC50 (mM) TGIa) (mM)
Curcumin 1060.5 2761.35
Pentamidine 13.561.35 .55.662.78
A 65% standard error was calculated for all the results, which is always associated
with hemocytometer counting. Each experiment was repeated thrice (n53). Curcumin
shows to be more potent against AALC as compared to pentamidine (t514.2,
p,0.001). a) TGI: Total growth inhibitory concentration.
